

DISCLAIMER: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



October 27, 2026

To whom it may concern,

Company name: Heartseed Inc.
Representative: Keiichi Fukuda, MD/PhD/FACC,
CEO, Representative Director of the Board
Securities code: 219A, Tokyo Stock Exchange
Inquiries: Akira Masuda, Head of Strategic Finance
and IR Department
TEL: +81-(0)3-6665-8068 (IR)

**Notice Regarding the First Patient Dosed in the Ischemic Heart Disease Cohort in the Phase I/II
company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac
Remuscularization Therapy**

Heartseed Inc. (the “Company”) hereby announces that, in its domestic clinical trial (EMERALD study) of HS-005 (allogeneic iPS cell-derived cardiomyocyte spheroids administered via catheter), the first patient with severe heart failure secondary to ischemic heart disease has been dosed. Based on four-week post-administration data, the Independent Safety Monitoring Committee has approved the continuation of the trial in this cohort.

This study aims to evaluate the safety and efficacy of the administration of HS-005 in patients with severe heart failure across two cohorts: ischemic heart disease and dilated cardiomyopathy (7 patients each, total of 14 patients). In the dilated cardiomyopathy cohort, following approval for trial continuation by the Independent Safety Monitoring Committee after dosing of the first patient (refer to "Notice Regarding the First Patient Dosed in the Phase I/II company-sponsored Clinical Trial of HS-005 (Catheter Administration) for Cardiac Remuscularization Therapy" disclosed on June 12, 2026), the enrollment of multiple patients has already been completed.

Please note that there is no revision to the latest earnings forecast for the fiscal year ending December 31, 2026.

(Cautionary notice on forward-looking information)

The financial results forecasts and other forward-looking information contained in this document are based on the information currently available to the Company and certain assumptions considered reasonable by the Company. It is not a guarantee that the forecasts will be achieved, and actual results may differ significantly from such forecasts depending on various factors.